New advances in the development of a vaccine against paracoccidioidomycosis

Imagem de Miniatura
Arquivos
art_TRAVASSOS_New_advances_in_the_development_of_a_vaccine_2012.PDF (1.18 MB)
Citações na Scopus
36
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS RESEARCH FOUNDATION
Autores
TRAVASSOS, Luiz R.
Citação
FRONTIERS IN MICROBIOLOGY, v.3, article ID 212, 6p, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Paracoccidioidomycosis (PCM) is an endemic Latin American mycosis caused by Paracoccidioides brasiliensis and also by the recently described P. lutzii. The systemic mycosis is the 10th leading cause of death due to infectious diseases in Brazil. As published, 1,853 patients died of PCM in the 1996-2006 decade in this country. The main diagnostic antigen of P brasiliensis is the 43 kDa glycoprotein gp43, and its 15-mer peptide QTLI-AIHTLAIRYAN, known as P10, contains the T-CD4(+) epitope that elicits an IFN-gamma-mediated Th1 immune response, which effectively treats mice intratracheally infected with PCM. The association of peptide P10 with antifungal drugs rendered an additive protective effect, even in immunosuppressed animals, being the basis of a recommended treatment protocol. Other immunotherapeutic tools include a peptide carrying a B cell epitope as well as protective anti-gp43 monoclonal antibodies. New delivery systems and gene therapy have been studied in prophylactic and therapeutic protocols to improve the efficacy of the recognized antigens aiming at a future vaccine as co-adjuvant therapy in patients with PCM.
Palavras-chave
P. brasiliensis, P. lutzii, paracoccidioidomycosis, vaccine, immunotherapy
URI
https://observatorio.fm.usp.br/handle/OPI/7962
Referências
  1. Amaral AC, 2010, BRIT J PHARMACOL, V159, P1126, DOI 10.1111/j.1476-5381.2009.00617.x
  2. Amorim J., 2010, THESIS U SAO PAULO S
  3. Arruda C, 2007, MICROBES INFECT, V9, P308, DOI 10.1016/j.micinf.2006.12.005
  4. Arruda C, 2007, MICROBES INFECT, V9, P704, DOI 10.1016/j.micinf.2007.02.014
  5. Batista J, 2010, MYCOSES, V53, P176, DOI 10.1111/j.1439-0507.2008.01687.x
  6. Braga CJM, 2009, INFECT IMMUN, V77, P1700, DOI 10.1128/IAI.01470-08
  7. Buissa-Filho R, 2008, INFECT IMMUN, V76, P3321, DOI 10.1128/IAI.00349-08
  8. Carvalho KC, 2005, MICROBES INFECT, V7, P55, DOI 10.1016/j.micinf.2004.09.008
  9. Cisalpino PS, 1996, J BIOL CHEM, V271, P4553
  10. Demicheli MC, 2007, MYCOSES, V50, P397, DOI 10.1111/j.1439-0507.2007.01389.x
  11. Demicheli MC, 2006, MYCOSES, V49, P184, DOI 10.1111/j.1439-0507.2006.01229.x
  12. Diniz SN, 2004, VACCINE, V22, P485, DOI 10.1016/j.vaccine.2003.07.017
  13. Martins EMD, 2009, MYCOPATHOLOGIA, V168, P51, DOI 10.1007/s11046-009-9197-5
  14. Fernandes VC, 2011, MICROBES INFECT, V13, P1062, DOI 10.1016/j.micinf.2011.06.004
  15. Fernandes VC, 2012, MYCOPATHOLOGIA, V174, P93, DOI 10.1007/s11046-012-9530-2
  16. Ferreira KS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015935
  17. Franco M, 1993, Curr Top Med Mycol, V5, P115
  18. Grosso DD, 2003, INFECT IMMUN, V71, P6534, DOI 10.1128/IAI.71.11.6534-6542.2003
  19. Iwai LK, 2007, CLIN VACCINE IMMUNOL, V14, P474, DOI 10.1128/CVI.00458-06
  20. Iwai LK, 2003, MOL MED, V9, P209
  21. Magalhaes A, 2012, CLIN VACCINE IMMUNOL, V19, P23, DOI 10.1128/CVI.05414-11
  22. Marques AF, 2006, ANTIMICROB AGENTS CH, V50, P2814, DOI 10.1128/AAC.00220-06
  23. Marques AF, 2008, MICROBES INFECT, V10, P1251, DOI 10.1016/j.micinf.2008.07.027
  24. Martins EMDN, 2007, VACCINE, V25, P7893, DOI 10.1016/j.vaccine.2007.09.011
  25. Matute DR, 2006, MOL BIOL EVOL, V23, P65, DOI 10.1093/molbev/msj008
  26. Mayorga O, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00154
  27. McEwen J G, 1995, Arch Med Res, V26, P305
  28. Pavanelli WR, 2007, MYCOPATHOLOGIA, V163, P117, DOI 10.1007/s11046-007-0095-4
  29. Pinto AR, 2000, VACCINE, V18, P3050, DOI 10.1016/S0264-410X(00)00074-8
  30. Prado M, 2009, MEM I OSWALDO CRUZ, V104, P513, DOI 10.1590/S0074-02762009000300019
  31. PUCCIA R, 1986, INFECT IMMUN, V53, P199
  32. PUCCIA R, 1991, ARCH BIOCHEM BIOPHYS, V289, P298, DOI 10.1016/0003-9861(91)90475-X
  33. Reis BS, 2008, VACCINE, V26, P5461, DOI 10.1016/j.vaccine.2008.07.097
  34. RESTREPO A, 1985, SABOURAUDIA, V23, P23
  35. Ribeiro AM, 2009, VACCINE, V27, P606, DOI 10.1016/j.vaccine.2008.10.022
  36. Ribeiro AM, 2010, VACCINE, V28, P1528, DOI 10.1016/j.vaccine.2009.11.062
  37. Rittner GMG, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001519
  38. RODRIGUES EG, 1994, J MED VET MYCOL, V32, P77
  39. Saraiva ECO, 1996, J MED VET MYCOL, V34, P155
  40. Shikanai-Yasuda M. A., 2005, EXPERT OPIN PHARMACO, V6, P385, DOI 10.1517/14656566.6.3.385
  41. Shikanai-Yasuda MA, 2006, REV SOC BRAS MED TRO, V39, P297, DOI 10.1590/S0037-86822006000300017
  42. Taborda CP, 2004, SCAND J IMMUNOL, V59, P58, DOI 10.1111/j.0300-9475.2004.01359.x
  43. Taborda CP, 1998, INFECT IMMUN, V66, P786
  44. Teixeira MM, 2009, MOL PHYLOGENET EVOL, V52, P273, DOI 10.1016/j.ympev.2009.04.005
  45. Travassos LR, 2004, PATHOGENIC FUNGI: HOST INTERACTIONS AND EMERGING STRATEGIES FOR CONTROL, P241
  46. Travassos L. R., 2011, J INVASIVE FUNGAL IN, V5, P1
  47. Travassos LR, 2004, MYCOTA, V12, P279
  48. Travassos LR, 2008, MYCOPATHOLOGIA, V165, P341, DOI 10.1007/s11046-007-9056-1
  49. Xander P, 2007, MICROBES INFECT, V9, P1484, DOI 10.1016/j.micinf.2007.08.001

Coleções
Artigos e Materiais de Revistas Científicas - LIM/53